Summary of the Conference Call on the Health Supplement CDMO Industry Industry Overview - The health supplement market in China is the second largest globally, with significant growth potential due to low penetration rates, approximately 1/4 to 1/5 of that in Europe and the US [1][4] - The largest segment is vitamin dietary supplements (EDS), accounting for about 60% of the market, with a noticeable trend towards functional foods [1][4] - The dual-track regulatory policy (registration + filing) has lowered entry barriers and accelerated product launches while enhancing regulatory oversight [1][5] Key Trends and Insights - Online channels have significantly impacted the health supplement market, achieving a penetration rate of around 60%, the highest globally, which has disrupted traditional offline channels [1][9] - Emerging brands are leveraging online platforms to target specific demographics, leading to a decline in traditional dietary supplement market share [1][9] - The concentration of brands and contract manufacturing in the health supplement industry is low, below 20%, with new online brands further dispersing market concentration [1][8] Regulatory Impact - The introduction of the dual-track system in 2016 has streamlined the approval process for new products, allowing for quicker market entry while increasing regulatory scrutiny to eliminate non-compliant products [5][7] - The 2019 Tianjin Qianjin incident led to stricter internal control mechanisms and a comprehensive industry cleanup, enhancing the overall transparency and standardization of the market [5][6] Consumer Demand and Behavior - Increasing income and health awareness among Chinese consumers are driving demand for health supplements, with a shift from serious health products to functional foods [6][12] - The traditional dietary supplement consumption patterns are evolving, with younger demographics becoming the primary consumers, influenced by the rise of online shopping [6][9] Company-Specific Insights Xianle Health - Xianle Health, a leading player in the health supplement CDMO sector, has achieved continuous revenue growth through international expansion and product innovation, despite profit fluctuations due to industry and global factors [3][13] - The acquisition of the US-based BF company has temporarily impacted profits but is expected to become a long-term growth driver [3][18] - Collaborations with new consumer brands have improved domestic revenue, with a notable partnership with brands like Dongfang Zhenxuan and Yang Men Dian [3][17] Baihe Co. - Baihe Co. has recently acquired New Zealand's Auri Company, which is expected to contribute to revenue growth [21] - The company has shown strong performance in the functional beverage sector, adapting well to new consumer demands despite being less focused on large client customization compared to Xianle [21] Future Outlook - The health supplement CDMO industry in China has substantial growth potential, with a current penetration rate of about 10%, lower than that of Europe and Japan (15%-20%) [12] - The high online penetration rate suggests a promising future for contract manufacturing, with expectations of increased demand driven by the rise of online sales channels [12][20] - Xianle plans to enhance cooperation with new consumer clients and expand into Southeast Asia through cross-border e-commerce and new factory setups [20]

Core Viewpoint - Xianle Health reported steady revenue growth and profitability in the first half of 2025, with a focus on expanding new consumer markets and optimizing business structure in response to challenges in specific segments [1][2][4]. Financial Performance - In H1 2025, the company achieved revenue of 2.04 billion yuan, a year-on-year increase of 2.6%, and a net profit attributable to shareholders of 160 million yuan, up 4.3% year-on-year [1]. - Q2 2025 revenue reached 1.09 billion yuan, reflecting a 4.7% year-on-year growth, while net profit was 90 million yuan, a 1.1% increase year-on-year [1]. Regional Performance - Revenue from the China region in H1 2025 was 820 million yuan, down 1.6% year-on-year, impacted by the Changqing market, although new consumer clients showed growth in revenue and online penetration [2]. - The Americas region generated 760 million yuan in H1 2025, a 4.3% increase year-on-year, with exports maintaining positive growth despite tariff disruptions [2]. - The European region performed strongly with H1 2025 revenue of 360 million yuan, up 22.0% year-on-year, exceeding sales targets [2]. - Other regions reported revenue of 100 million yuan, down 23.0% year-on-year [2]. Product Segment Performance - Revenue growth by product type in H1 2025 included soft capsules (+6.5%), tablets (+33.4%), gummies (+6.35%), and hard capsules (+11.0%), while powder (-36.0%) and beverages (-20.8%) saw declines [2]. Profitability and Cost Management - The company's gross margin improved by 1.13 percentage points to 33.2% in H1 2025, attributed to lean production and cost reduction efforts [3]. - In Q2 2025, the gross margin slightly decreased by 0.1 percentage points to 33.3%, likely due to disruptions in the BF business [3]. - The net profit margin for Q2 2025 was 8.5%, down 0.3 percentage points year-on-year [3]. Future Outlook - The company anticipates stable recovery in domestic business and continued growth in new consumer markets, with potential in high-growth areas like pet nutrition [4]. - The successful divestiture of the BFPC segment could enhance profit elasticity and overall growth [4]. - Revenue forecasts for 2025 to 2027 are projected at 4.492 billion, 5.104 billion, and 5.863 billion yuan, with net profits of 350 million, 460 million, and 570 million yuan respectively [4].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][10] Core Views - The company's revenue for 2024 reached 4.211 billion yuan, a year-on-year increase of 17.56%, with a net profit attributable to shareholders of 0.325 billion yuan, up 15.66% year-on-year [6] - In Q1 2025, the company achieved revenue of 0.954 billion yuan, a slight increase of 0.28% year-on-year, and a net profit of 0.069 billion yuan, up 8.90% year-on-year [6] - The company is positioned as a leading CDMO in the health food industry, with a focus on product innovation and technological upgrades, supported by a global supply capability across China, the US, and Europe [9] Summary by Sections Recent Performance - The company's performance in the last year shows a mixed trend, with a 1-month decline of 4.7% and a 12-month decline of 9.5% compared to the CSI 300 index [4] - As of April 25, 2025, the current stock price is 25.41 yuan, with a market capitalization of approximately 6.029 billion yuan [4] Regional Performance - In 2024, revenue by region was as follows: China 1.661 billion yuan (down 10.28%), Europe 0.604 billion yuan (up 14.25%), Americas 1.666 billion yuan (up 59.56%), and other regions 0.280 billion yuan (up 77.38%) [6] - The Chinese market showed signs of recovery in Q1 2025, with revenue stabilizing due to the company's efforts in expanding new consumer markets [6] Product Performance - In 2024, revenue by product type was: soft capsules 1.984 billion yuan (up 29.91%), tablets 0.326 billion yuan (down 10.05%), powders 0.232 billion yuan (down 20.90%), gummies 0.995 billion yuan (up 34.54%), beverages 0.248 billion yuan (down 41.22%), hard capsules 0.223 billion yuan (up 46.83%), and other forms 0.177 billion yuan (up 141.32%) [6] - The company has seen significant growth in high-margin products like gummies, which have increased their market share from approximately 5% in 2022 to nearly 10% in 2024 [6] Profitability - The gross margin for 2024 was 31.46%, improving to 33.09% in Q1 2025, reflecting a year-on-year increase of 1.19 percentage points and 2.47 percentage points respectively [6] - The company’s net profit margin for 2024 was 7.72%, slightly decreasing to 7.19% in Q1 2025 [7] Financial Forecast - The projected revenue for 2025 is 4.663 billion yuan, with a net profit of 0.400 billion yuan, and EPS of 1.69 yuan [8] - The company expects a revenue growth rate of 11% in 2025, with a net profit growth rate of 23% [8] Competitive Position - The company is enhancing its competitive barriers through multi-dimensional capability improvements, including product innovation, supply chain optimization, and digital transformation [9] - The company’s innovative products contributed over 35% to sales in 2024, with higher gross margins than average [9]